4D Molecular Therapeutics's market cap is currently $215.88M. The company's EPS TTM is $-2.734; its P/E ratio is ―; 4D Molecular Therapeutics is scheduled to report earnings on March 31, 2025, and the estimated EPS forecast is $-0.83. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 20.72M	$ 3.13M	$ 18.04M	$ 13.61M	$ 6.99M
Gross Profit	$ -76.37M	$ -751.00K	$ 15.02M	$ -39.43M	$ -31.73M
Operating Income	$ -112.87M	$ -110.03M	$ -71.33M	$ -56.66M	$ -50.76M
EBITDA	$ -107.12M	$ -106.15M	$ -68.31M	$ -55.22M	$ -44.62M
Net Income	$ -100.84M	$ -101.08M	$ -68.30M	$ -56.54M	$ -52.94M
Balance Sheet
Cash & Short-Term Investments	$ 288.23M	$ 218.64M	$ 315.43M	$ 276.73M	$ 49.65M
Total Assets	$ 339.89M	$ 261.85M	$ 353.49M	$ 288.33M	$ 58.23M
Total Debt	$ 14.67M	$ 16.12M	$ 16.45M	$ 0.00	$ 0.00
Net Debt	$ -234.44M	$ -202.52M	$ -298.98M	$ -276.73M	$ -49.65M
Total Liabilities	$ 32.06M	$ 30.51M	$ 560.48M	$ 31.94M	$ 131.20M
Stockholders' Equity	$ 307.83M	$ -314.49M	$ -207.00M	$ 256.39M	$ -72.97M
Cash Flow
Free Cash Flow	$ -78.56M	$ -98.22M	$ -78.24M	$ -51.91M	$ -39.91M
Operating Cash Flow	$ -75.79M	$ -86.69M	$ -69.13M	$ -50.91M	$ -36.71M
Investing Cash Flow	$ 115.72M	$ -17.05M	$ -172.68M	$ -1.00M	$ -3.20M
Financing Cash Flow	$ 156.83M	$ 3.08M	$ 118.09M	$ 278.98M	$ -2.19M

Currency in USD

4D Molecular Therapeutics Earnings and Revenue History

Income Statement >

4D Molecular Therapeutics Debt to Assets

Balance Sheet >

4D Molecular Therapeutics Cash Flow

Cash Flow >

4D Molecular Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing